Pfizer has paid US$725 M for Medivation’s Alzheimer’s drug, Dimebon™. Unlike drugs such as Flurizan® (tarenflurbil) and bapineuzumab, which have stumbled in clinical trials, Dimebon has demonstrated significant benefit to Alzheimer’s sufferers in Phase III clinical trials and offers a new approach to treat the disease.